Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin/dapagliflozin plus metformin versus insulin glargine plus metformin in adults with LADA
2015-004723-31Phase 2Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Jun 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in latent autoimmune diabetes in adults (LADA) comparing Saxagliptin/dapagliflozin + metformin with Insulin glargine + metformin (2 arms). Primary endpoint: Change in C-peptide AUC during mixed meal tolerance test. Started Jun 2021; status: completed.
02
Drugs
saxagliptindapagliflozinmetformininsulin glargine
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on 2015-004723-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004723-31.